NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune ...

GammaDelta’s drug platform is based on the unique properties of gamma delta (γδ) T cells, a class of lymphocytes that play a role to many types of immune responses and immunopathology.

If you are looking for ways to contrast subsets, characterize mechanisms of action, and optimize product design to enhance your gamma delta clinical pipeline and develop globally accessible solid ...

The platform’s first candidate, INB-619, targets CD19, a key marker broadly found on B cells, which play a central role in leukemias, lymphomas, and autoimmune diseases. In preclinical models, INB-619 ...

Adicet Bio, Inc. (NASDAQ:ACET), a clinical-stage biopharmaceutical company with a market capitalization of $65.5 million, focuses on developing engineered gamma-delta T cell therapies. The company ...

Senior Caitlin May was the first rider up for Delta Gamma. The anticipation in the crowd continued to build as the cheers ...

Phi Gamma Delta’s national organization has temporarily suspended the UCF chapter and stated it does not condone hazing or ...

Adicet Bio, Inc. is a clinical stage biotechnology company, which engages in discovering and developing allogeneic gamma delta T cell therapies for cancer. It also focuses on developing a pipeline ...

NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune ...

Poster Title: A novel gamma-delta T cell engager platform for cancer immunotherapy Session Title: Immunology/T Cell Engagers and Novel Antibody-Based Therapies Session Date and Time: Wednesday, April ...